
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Diagnosing allergic diseases : Why knowing the history is as important as the test Managing vomiting : Should I consider options besides rehydration? Puzzler : Dressing up as fever and a rash Dermcase : Lesions expand at blistering speed in baby boy






